Secondary analysis of a phase III trial in 86 patients with metastatic GIST: fourth-line pimitespib vs placebo left quality of life generally similar, except worse diarrhoea (HR 4.82 for ≥10-point deterioration) and appetite loss.
Secondary analysisn = 86
Komatsu et al. Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study